Jack Barbut joined NovImmune as CEO since 2001. He is the former President and Chief Executive Officer of Synarc Inc, San Francisco, (1998-2000) with more than 20 years of professional experience in clinical trials management and drug development. Prior to joining Synarc, Jack Barbut was the founder, Vice-Chairman and President of Clinical Services of Chrysalis International, Inc., (1981-1998) a publicly (NASDAQ) traded global full service, Contract Research Organization (CRO), with 450 employees, USD 60M in sales and USD 150 M in market capitalization when it went public. Today it is part of MDS (NYSE), a global drug development service company with USD 1.2 billion in sales and 11,000 employees. A Swiss citizen, Jack Barbut holds a MS in Electrical Engineering and a ScD in Systems Engineering from the EPFL in Lausanne, Switzerland.